Loading...
Loading...
Jefferies analysts Scott Mushkin, Bakley Smith, and Mike Otway are concerned about potential downside to Walgreen
WAG. They maintained their Hold rating, however, due to the unpredictability of the situation with CVS/Caremark
CVS.
CVS/Caremark and Walgreens have drawn a line in the sand, and neither side is giving indications of a compromise. An interview with Walgreen CEO Greg Wasson gave indication that the company is preparing for business as usual without Caremark.
"We sharpened our analysis from yesterday and, although the situation remains highly fluid, it indicates up to $1.00 of EPS is at risk in fiscal '11, assuming the company is unable to replace lost revenue quickly."
Jefferies' target price for WAG stayed at $36.00. WAG is currently trading at $29.83.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in